CTOR vs PSA · $105.2M cap vs rev $4.82B
Citius Oncology, Inc. (CTOR) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Citius Oncology, Inc. (CTOR) is a drug manufacturers - specialty & generic company listed on US.
PSA (PSA) common stock.
CTOR does not have a complete income-statement cache yet.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
CTOR currently screens at market cap $105.2M. PSA currently screens at market cap $0.
Not investment advice. Open the CTOR and PSA stock pages for the full models.
Not investment advice.